Bert A. van der Reijden

8.5k citations

93 papers · 3.7k indexed · 2 hit papers · h-index 29

Hematology top 0.5%
- Acute Myeloid Leukemia Research 55
Genetics top 1%
- Blood disorders and treatments 11
- Myeloproliferative Neoplasms: Diagnosis and Treatment 11
Cancer Research top 5%
- Cancer Genomics and Diagnostics 8
Molecular Biology top 5%
- Ubiquitin and proteasome pathways 10
- Epigenetics and DNA Methylation 10
- Protein Degradation and Inhibitors 8
- Retinoids in leukemia and cellular processes 7
Immunology top 10%

Co-authors: Joop H. Jansen Théo de Witte Ruth Knops Marion Massop Saskia Langemeijer Roland P. Kuiper Peter Vandenberghe Gorica Nikoloski
Cited by: Hematology Genetics Cancer Research
Journals: Nature Genetics (2 papers)Journal of Clinical Oncology (2 papers)The EMBO Journal (1 paper)
Partner nations: Netherlands Germany United States

In The Last Decade

Bert A. van der Reijden

90 papers receiving 3.7k citations

Hit Papers

align trajectories log scale

Peers

Countries citing papers authored by Bert A. van der Reijden

Since Specialization

Citations

This map shows the geographic impact of Bert A. van der Reijden's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Bert A. van der Reijden with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Bert A. van der Reijden more than expected).

Fields of papers citing papers by Bert A. van der Reijden

Since Specialization

Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Bert A. van der Reijden. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Bert A. van der Reijden. The network helps show where Bert A. van der Reijden may publish in the future.

Co-authorship network

The 25 scholars most cited alongside Bert A. van der Reijden, linked wherever they have co-authored with each other. Click a name or a connecting line to browse the papers they share.

Border = papers with Bert A. van der Reijden Line = papers co-authored together Bert A. van der Reijden links everyone, so they are left out of the graph.

All Works

Sort: Min cites: Since: Top N: Style:

20 of 20 papers shown

#	Work
1	Intraperitoneal infusion of stem cell-derived natural killer cells in recurrent epithelial ovarian cancer patients: Results of the phase 1 INTRO-01 trial Gynecologic Oncology ·Janneke S. Hoogstad‐van Evert,Paul K.J.D. de Jonge,Petra L.M. Zusterzeel,Willemijn Hobo,Anniek B. van der Waart,Hanny Fredrix,Lisanne M. A. Janssen,Maud Wuts,Lynn Bosmans,Ellen Spijkers,Merlize Djojoatmo,Vanessa Rodríguez‐Fanjul,Anna L. de Goede,Bert A. van der Reijden,Arnold van der Meer,Nicolaas Schaap,Ruud L.M. Bekkers,Joop H. Jansen,Nelleke Ottevanger,Harry Dolstra	2025	1
2	Acute myeloid leukemia associated RUNX1 variants induce aberrant expression of transcription factor TCF4 Leukemia ·Mylène Gerritsen,Florentien E. M. in ’t Hout,Ruth Knops,Bas L R Mandos,Melanie Decker,Tim Ripperger,Bert A. van der Reijden,Joost H.A. Martens,Joop H. Jansen	2024	1
3	HMX3 is a critical vulnerability in MECOM-negative KMT2A::MLLT3 acute myelomonocytic leukemia Leukemia ·Saioa Arza-Apalategi,Branco M. H. Heuts,Saskia M. Bergevoet,Roos Meering,Daan Gilissen,Pascal W.T.C. Jansen,Anja Krippner‐Heidenreich,Peter J.M. Valk,Michiel Vermeulen,Olaf Heidenreich,Torsten Haferlach,Joop H. Jansen,Joost H.A. Martens,Bert A. van der Reijden	2024	2
4	Erythroid Predominance in Bone Marrow Biopsies of Acute Myeloid Leukemia Patients after Decitabine Treatment Correlates with Mutation Profile and Complete Remission Pathobiology ·Francesca Tiso,Konnie M. Hebeda,Saskia Langemeijer,Aniek O. de Graaf,Joost H.A. Martens,Thessa N Koorenhof-Scheele,Ruth Knops,Leonie I. Kroeze,Bert A. van der Reijden,Joop H. Jansen	2024	0
5	Improvement, Implementation, and Evaluation of the CMyLife Digital Care Platform: Participatory Action Research Approach Journal of Medical Internet Research ·Lynn Verweij,Sanne J J P M Metsemakers,Geneviève I. C. G. Ector,Peter Rademaker,Charlotte L. Bekker,Bas van Vlijmen,Bert A. van der Reijden,Nicole M. A. Blijlevens,Rosella Hermens	2023	2
6	Effectiveness of digital care platform CMyLife for patients with chronic myeloid leukemia: results of a patient-preference trial BMC Health Services Research ·Lynn Verweij,Geneviève I. C. G. Ector,Yolba Smit,Bas van Vlijmen,Bert A. van der Reijden,Rosella Hermens,Nicole M. A. Blijlevens	2023	5
7	Inducible MLL-AF9 Expression Drives an AML Program during Human Pluripotent Stem Cell-Derived Hematopoietic Differentiation Cells ·Branco M. H. Heuts,Saioa Arza-Apalategi,Sinne Alkema,Esther Tijchon,Laura Jussen,Saskia M. Bergevoet,Bert A. van der Reijden,Joost H.A. Martens	2023	6
8	Evolutionary landscape of clonal hematopoiesis in 3,359 individuals from the general population Cancer Cell ·Isabelle A. van Zeventer,Aniek O. de Graaf,Jonas B. Salzbrunn,Ilja M. Nolte,Priscilla Kamphuis,Avinash G. Dinmohamed,Bert A. van der Reijden,Jan Jacob Schuringa,Joop H. Jansen,Gerwin Huls	2023	38
9	Multicenter Next-Generation Sequencing Studies between Theory and Practice Journal of Molecular Diagnostics ·Sarah Sandmann,Aniek O. de Graaf,Magnus Tobiasson,Olivier Kosmider,María Abáigar,Emmanuelle Clappier,Anna Gallì,Bert A. van der Reijden,Luca Malcovati,Pierre Fenaux,María Díez‐Campelo,Michaëla Fontenay,Eva Hellström‐Lindberg,Joop H. Jansen,Martin Dugas	2020	3
10	Evaluating Variant Calling Tools for Non-Matched Next-Generation Sequencing Data Scientific Reports ·Sarah Sandmann,Aniek O. de Graaf,Mohsen Karimi,Bert A. van der Reijden,Eva Hellström‐Lindberg,Joop H. Jansen,Martin Dugas	2017	121
11	Apoptosis-Related Gene Expression Profiling in Hematopoietic Cell Fractions of MDS Patients PLoS ONE ·Saskia Langemeijer,Niccolò Mariani,Ruth Knops,Christian Gilissen,Rob Woestenenk,Théo de Witte,Gerwin Huls,Bert A. van der Reijden,Joop H. Jansen	2016	15
12	ANALYSIS OF NEW GFI1B VARIANTS IN PATIENTS WITH INHERITED BLEEDING AND PLATELET DISORDERS Haematologica ·Anna E. Marneth,Ruud van Oorschot,Saskia M. Bergevoet,Anouck Wijgaerts,Ernest Turro,B. A Laros-van Gorkom,Waander L. van Heerde,Gerwin Huls,J. Jansen,Willem H. Ouwehand,Kate Downes,Kathleen Freson,Bert A. van der Reijden	2015	2
13	Gfi1 as a new target and predictive marker in AML Experimental Hematology ·Judith Hönes,Lacramioara Botezatu,Lars Michel,Christian Thiede,Bert A. van der Reijden,Michael Heuser,Peter J.M. Valk,Bob Löwenberg,Hideki Makishima,Gerhard Ehninger,Ulrich Duehrsen,Jaroslaw P. Maciejewski,Tarik Möröy,Cyrus Khandanpour	2014	1
14	BCL-2/IgH Polymerase Chain Reaction Status at the End of Induction Treatment Is Not Predictive for Progression-Free Survival in Relapsed/Resistant Follicular Lymphoma: Results of a Prospective Randomized EORTC 20981 Phase III Intergroup Study Journal of Clinical Oncology ·Marinus H. J. van Oers,Evelyn Tönnissen,M. van Glabbeke,L. Giurgea,Joop H. Jansen,Richard Klasa,Robert Marcus,Max Wolf,Eva Kimby,Andrej Vranovský,Harald Holte,Anton Hagenbeek,Bert A. van der Reijden	2010	34
15	MicroRNA hsa-miR-135b Regulates Mineralization in Osteogenic Differentiation of Human Unrestricted Somatic Stem Cells Stem Cells and Development ·Aneta Oziemlak,Reinier Raymakers,Saskia M. Bergevoet,Christian Gilissen,Bas Jansen,Gosse J. Adema,Gesine Kögler,Carlos le Sage,Reuven Agami,Bert A. van der Reijden,Joop H. Jansen	2009	83
16	The ubiquitin ligase Triad1 inhibits myelopoiesis through UbcH7 and Ubc13 interacting domains Leukemia ·Jurgen A. Marteijn,Laurens T. van der Meer,Judith J. Smit,Sylvie M. Noordermeer,Willemijn Wissink,Patrick A.M. Jansen,Herman G.P. Swarts,Richard G. Hibbert,T. de Witte,Titia K. Sixma,Joop H. Jansen,Bert A. van der Reijden	2009	27
17	Isolation of FRET‐positive cells using single 408‐nm laser flow cytometry Cytometry Part A ·Sake van Wageningen,Arie Pennings,Bert A. van der Reijden,J.B.M. Boezeman,Frank de Lange,Joop H. Jansen	2006	12
18	Bcl-2 prevents loss of mitochondria in CCCP-induced apoptosis Experimental Cell Research ·Aniek O. de Graaf,Lambert P. van den Heuvel,Henry Dijkman,Ronney A. De Abreu,Kim U. Birkenkamp,Théo de Witte,Bert A. van der Reijden,Jan Smeıtınk,Joop H. Jansen	2004	83
19	Minimal residual disease quantification in patients with acute myeloid leukaemia and inv(16)/CBFB‐MYH11 gene fusion British Journal of Haematology ·Bert A. van der Reijden,Annet Simons,Erna B Luiten,Sonja C. Van Der Poel,Pauline Hogenbirk,Evelyn Tönnissen,Peter J.M. Valk,Bob Löwenberg,Georgine E. de Greef,Martijn H. Breuning,Joop H. Jansen	2002	27
20	Identification of a novel CBFB-MYH11 transcript: implications for RT–PCR diagnosis The Hematology Journal ·Bert A. van der Reijden,Linda de Wit,Sonja van der Poel,Erna B Luiten,Mårina Lafage‐Pochitaloff,Nicole Dastugue,Jean Gabert,Bob Löwenberg,Joop H. Jansen	2001	19

About Bert A. van der Reijden

Bert A. van der Reijden is a scholar working on Hematology, Genetics and Family Practice, having authored 93 papers that have together received 3.7k indexed citations. Recurring topics across this work include Acute Myeloid Leukemia Research (55 papers), Blood disorders and treatments (11 papers), Myeloproliferative Neoplasms: Diagnosis and Treatment (11 papers), Ubiquitin and proteasome pathways (10 papers), Epigenetics and DNA Methylation (10 papers), Cancer Genomics and Diagnostics (8 papers), Protein Degradation and Inhibitors (8 papers) and Retinoids in leukemia and cellular processes (7 papers). The work is most often cited by research in Hematology (1.8k citations), Genetics (634 citations) and Cancer Research (554 citations). Bert A. van der Reijden has collaborated with scholars based in Netherlands, Germany and United States. Frequent co-authors include Joop H. Jansen, Théo de Witte, Ruth Knops, Marion Massop, Saskia Langemeijer, Roland P. Kuiper, Peter Vandenberghe, Gorica Nikoloski, Reinier Raymakers and Laurens T. van der Meer. Their work appears in journals such as Nature Genetics, Journal of Clinical Oncology and The EMBO Journal.

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact